- Conditions
- Alzheimer's Disease
- Interventions
- Solanezumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 2,129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 120
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 93 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 866
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertension, Heart Failure
- Interventions
- Clevidipine, Standard of Care IV antihypertensive
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 9
- States / cities
- Montgomery, Alabama • Inglewood, California • Baton Rouge, Louisiana + 6 more
- Conditions
- High Cholesterol
- Interventions
- 5 mg rosuvastatin calcium with a Web App (combination product)
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 20 Years to 75 Years
- Enrollment
- 1,196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Cigarette Smoking Toxicity
- Interventions
- Menthol to non-menthol
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Schizophrenia
- Interventions
- Magstim Rapid 2 system triggering Magstim Super Rapid system
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- NNRTI, FTC/TDF, Stribild
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 439 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Hayward, California + 29 more
- Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
- Interventions
- TAK-755, Standard of care
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 0 Years to 70 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Las Vegas, Nevada • Durham, North Carolina + 4 more
- Conditions
- Neurogenic Orthostatic Hypotension
- Interventions
- Sinosuidal Galvanic Vestibular Stimulation, Placebo
- Device
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Entospletinib, Daunorubicin, Cytarabine, Decitabine, Azacitidine
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Chicago, Illinois • Maywood, Illinois + 10 more
- Conditions
- Migraine
- Interventions
- 0.5% bupivicaine and 2% lidocaine, Saline placebo
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- HIV-Associated Lipodystrophy Syndrome
- Interventions
- Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs), continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 4
- States / cities
- Fort Lauderdale, Florida • Honolulu, Hawaii • Huntersville, North Carolina + 1 more
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- Stribild
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 3 more
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Interventions
- FOCAL+, VR-FOCAL+
- Behavioral
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 16 Years to 19 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma, Synovial Sarcoma
- Interventions
- Lymphodepletion, TCR-T cells (MDG1015)
- Drug · Biological
- Lead sponsor
- Medigene AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- HIV, HIV-associated Neurocognitive Disorder, Neurotoxicity
- Interventions
- Raltegravir
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Malocclusion
- Interventions
- Invisalign (7 day), Invisalign (5 day), OrthoPulse, Invisalign (3.5 day)
- Device
- Lead sponsor
- Biolux Research Holdings, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Chandler, Arizona • Maple Grove, Minnesota • Henderson, Nevada + 1 more
- Conditions
- Nephrotoxicity
- Interventions
- Belatacept
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- HIV-1 Infection
- Interventions
- F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Interventions
- Tirzepatide, Zenagamtide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Glendale, California • Baltimore, Maryland
- Conditions
- Bariatric Surgery Candidate, Severe Obesity
- Interventions
- Single Anastomosis Duodenal Ileal Bypass (SADI)
- Procedure
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- BRAF V600E Negative, KRAS Gene Mutation Negative, Locally Advanced Unresectable Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, NRAS Gene Mutation Negative, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Cetuximab, Irinotecan, Panitumumab, Regorafenib
- Biological · Drug
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 12 more
- Conditions
- Obesity
- Interventions
- Mayo Clinic Diet, Usual Care
- Behavioral
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Triumeq
- Drug
- Lead sponsor
- Mills Clinical Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Alzheimer's Disease
- Interventions
- Remternetug (IV), Remternetug (SC), Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 1,667 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 73
- States / cities
- Chandler, Arizona • Canoga Park, California • Carlsbad, California + 66 more